Survodutide

Protocol examples

Protocol logic check

Independent evidence

Regulatory status: investigational not FDA approved

Storage

No approved-label storage guidance was identified for this entry. Use conservative sterile handling and see the general storage guidance in the FAQ.

Contraindications & cautions

Evidence varies by item. Some points come from labels, published literature, or regulatory context; others are mechanism-based cautions from the source dataset. Use the sources below to verify details.

• Personal or family history of Medullary Thyroid Carcinoma (MTC).
• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
• Personal or family history of thyroid C-cell tumors.
• Pre-existing tachycardia, cardiac arrhythmias, or cardiovascular instability: glucagon receptor backbone increases sympathomimetic tone.
• Uncontrolled hypertension.
• Active or history of acute pancreatitis.
• Severe gastroparesis or clinically significant delayed gastric emptying.
• Type 1 diabetes mellitus.
• Diabetic ketoacidosis.
• Pregnancy: insufficient safety data; discontinue prior to planned conception.
• Breastfeeding: insufficient safety data.
• Known hypersensitivity or anaphylaxis to survodutide or any formulation excipient.
• Concurrent use with any other GLP-1 receptor agonist, glucagon receptor agonist, or dual/triple incretin agonist: direct pharmacological conflict.
• Concomitant use of insulin or sulfonylureas without dose adjustment: significantly elevated hypoglycemia risk.
• Severe inflammatory bowel disease or active Crohn's disease: GI motility impairment may worsen symptoms.
• Planned general anesthesia or elective surgery: delayed gastric emptying raises pulmonary aspiration risk; follow pre-operative fasting protocols.
• Severe hepatic impairment: glucagon receptor-mediated hepatic metabolism alterations limit safety data applicability.
• End-stage renal disease: safety not established.
• Pediatric use: safety and efficacy not established.

Possible side effects

Evidence varies by item. Some points come from labels, published literature, or regulatory context; others are mechanism-based cautions from the source dataset. Use the sources below to verify details.

• Nausea: reported in 40-66% of subjects at therapeutic doses; highest GI adverse event rate among the dual agonist class.
• Vomiting: reported in 15-41% of subjects; most frequent during dose escalation phases.
• Diarrhea: reported in 25-49% of subjects.
• Abdominal pain and cramping.
• Constipation.
• Abdominal distension and bloating.
• Decreased appetite: a direct pharmacological effect contributing to weight loss.
• Dysgeusia (altered taste).
• Gastroparesis: delayed gastric emptying; clinically relevant for surgical anesthesia planning.
• Gastroesophageal reflux disease (GERD) exacerbation.
• Fatigue and lethargy: frequently secondary to caloric deficit.
• Elevated resting heart rate: mean increase of 2-5 BPM; modest but consistent; patients with underlying cardiac conditions should monitor closely.
• Headache.
• Dizziness.
• Hypoglycemia: low risk in monotherapy; significantly elevated risk with concomitant insulin or sulfonylureas.
• Acute pancreatitis: class risk; discontinue immediately if severe abdominal pain radiating to the back develops.
• Cholelithiasis (gallstones) and acute cholecystitis: risk increases with rapid weight loss.
• Liver enzyme elevations (transaminases): transient; monitor during initial treatment phase.
• Thyroid C-cell tumor risk: confirmed in rodent models; human risk not established; monitor for neck mass, hoarseness, or dysphagia.
• Alopecia (hair loss): reported across the incretin class; likely secondary to rapid caloric restriction.
• Injection site reactions: redness, swelling, itching; transient and self-resolving.
• Anaphylaxis and angioedema: rare but documented across the incretin class.
• Pulmonary aspiration risk under general anesthesia: secondary to delayed gastric emptying.
• Higher discontinuation rate than comparator agents: GI tolerability profile more demanding than pure GLP-1 agonists; slow titration is essential.
• Rapid weight regain upon discontinuation: expected without sustained lifestyle intervention.

Compatibility

The relationships below come from the source site's internal engine and were not verified independently. Treat them as a starting point for a conversation with a clinician. They carry no safety guarantee.

Reported synergistic:

Reported contraindicated combinations:

Sources

• https://the source dataset.com/peptide-codex.php
• https://www.fda.gov/drugs/guidance-compliance-regulatory-information/human-drug-compounding
• https://pubmed.ncbi.nlm.nih.gov/38330987/
• https://pubmed.ncbi.nlm.nih.gov/42253238/
• PubMed search: Survodutide
• PubMed trial search: survodutide obesity phase 2